Clinical entities described to be associated as MEN 1 are: hyperparathyroidism (95%), enteropancreatic tumors (30-80%), pituitary adenomas (most frequent prolactinoma, followed by growth hormone secreting tumors; 20-25%), carcinoid tumors (20%), adrenal adenomas (40%) and subcutaneous lipomas (30%) [11]. Here, GH1 is linked to hyperparathyroidism.